Navigation Links
China Cord Blood Corporation Files Its Annual Report on Form 20-F/A
Date:10/20/2010

China Cord Blood Corporation Files Its Annual Report on Form 20-F/A -- HONG KONG, Oct. 20 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Accounting News & Issues Click to view news release full screen  

China Cord Blood Corporation Files Its Annual Report on Form 20-F/A

 

HONG KONG, Oct. 20 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ("CCBC" or "the Company") (NYSE: CO), the first and largest cord blood bank operator in China, today announced that the Company has filed an amendment to its Annual Report on Form 20-F/A, which included audited financial statements for the fiscal year ended March 31, 2010 with the U.S. Securities and Exchange Commission. The Form 20-F/A can be accessed by visiting the U.S. Securities and Exchange Commission's website at www.sec.gov and can also be found at CCBC's website at http://www.chinacordbloodcorp.com , under Investor Relations. CCBC will provide a hard copy of the Annual Report, including a complete set of audited financial statements, free of charge to any shareholder upon request.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com .

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact: China Cord Blood Corporation Ms. Joeling Law Tel: +852-3605-8180 Email: ir@chinacordbloodcorp.com ICR, LLC In New York: Ashley M. Ammon or Christine Duan Tel: +1-646-277-1227 In Beijing: Wen Lei Zheng Tel: +86-10-6599-7968
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Industrial Biotechnology China News 1009
2. According to Opurity, Feds Put U.S. Consumers at Risk: PTO Bureaucrats Refuse to Approve Vitamin Companys China-Free Trademark
3. Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco
4. China Cord Blood Corporation Updates Status Regarding Share Repurchase Program
5. China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic
6. China-Biotics Hosted its First Investor Day Event
7. Cord Blood America CEO Matthew Schissler Discusses Projects in China, South America, Afford-A-Cord, and Profitability
8. China Cord Blood Corporation to Launch Warrant Exchange Offer
9. China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results
10. China-Biotics Ranked Number 62 on FORTUNES 100 Fastest-Growing Companies List
11. Reportlinker Adds Advances in Biopharmaceutical Technology in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
Breaking Biology News(10 mins):